Gabapentin Market Size, Growth, Trends | Report 2023-2032
The global gabapentin market size was estimated at around USD 1.5 billion in 2022 and it is projected to hit around USD 1.77 billion by 2032, growing at a CAGR of 1.67% from 2023 to 2032.
Gabapentin belongs to class of anticonvulsants. The medication is prescribed for the control of seizures in the treatment of epilepsy. According to WHO, nearly 5 million individuals worldwide suffer from epilepsy, a persistent brain disorder. Epilepsy is one of the most common neurological disorders, which is characterized by recurring seizures, which are brief bursts of uncontrollable movement that can affect either a small portion of the body (partial) or the entire body (generalized). They can also occasionally be followed by loss of control and consciousness over bowel or bladder function.
Report Scope of the Gabapentin Market
| Report Coverage | Details |
| Market Size in 2022 | USD 1.5 billion |
| Revenue Forecast by 2032 | USD 1.77 billion |
| Growth rate from 2023 to 2032 | CAGR of 1.67% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Apotex Inc., GSK plc, Alkem Labs, and Jiangsu Nhwa Pharmaceutical Co., Ltd. |
The rise in geriatric population, increasing investments in R&D by pharmaceutical companies, rise in government efforts, ease of purchase, and rising product approvals are all factors that are expected to fuel market growth. Moreover, increasing awareness, for instance, November is celebrated as National Epilepsy Awareness Month (NEAM) which helps in spreading awareness and taking up steps and initiatives to understand and help control the condition further propelling the growth of the market. However, it is anticipated that the lack of health reimbursement policies, high cost and side effects associated with gabapentin, and rigorous regulatory policies is expected to restrain the market growth.
Gabapentin was originally developed and prescribed for the treatment of epilepsy and seizures. However, in recent years, the prescription has increased 5-fold owing to a growing number of doctors prescribing gabapentin "off-label" for both acute and chronic pain. Some are even prescribing it in place of opioids, while others prescribe it along with opioids.
North America dominated the overall market in 2022 which can be attributed to the growing population being diagnosed with central nervous system disorders that further causes seizures. It is seen that around 1 in every 26 people in U.S. are diagnosed with epilepsy. Moreover, the region shows a high incidence of geriatric population that is more prone to CNS disorder. It is estimated that the incidence of epilepsy is around 85 per 100,000 for people who are aged 65-69 years and the incidence rate rises with increasing age of an individual owing to associated risk factors for epilepsy being more common in older adults.
Major companies operating in the market are focusing on product launches and geographical expansion to maintain their presence in the market. For instance, in December 2020, Glenmark Pharmaceuticals Limited received ANDA approval for Gabapentin Enacarbil Extended-Release Tablets.
Gabapentin Market Segmentations:
| By Product Type | By Application | By Route of Administration | By Distribution Channel |
|
Tablets Capsule |
Epilepsy Neuropathic Pain Restless Legs Syndrome |
Oral Parenteral Injectable |
Hospital Pharmacy Retail Pharmacy Online Pharmacy |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gabapentin Market
5.1. COVID-19 Landscape: Gabapentin Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gabapentin Market, By Product Type
8.1. Gabapentin Market, by Product Type, 2023-2032
8.1.1. Tablets
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Capsule
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Gabapentin Market, By Application
9.1. Gabapentin Market, by Application, 2023-2032
9.1.1. Epilepsy
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Restless Legs Syndrome
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Gabapentin Market, By Route of Administration
10.1. Gabapentin Market, by Route of Administration, 2023-2032
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Gabapentin Market, By Hospital Pharmacy
11.1. Gabapentin Market, by Distribution Channel, 2023-2032
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Online Pharmacy
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Gabapentin Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.1.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.2.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.3.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.4.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product Type (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 13. Company Profiles
13.1. Glenmark Pharmaceuticals Limited
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Sun Pharmaceutical Industries Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Apotex Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. GSK plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Alkem Labs
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Jiangsu Nhwa Pharmaceutical Co., Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers